Lantern Pharma Stock Z Score
| LTRN Stock | USD 3.75 0.18 4.58% |
Lantern | Z Score |
Lantern Pharma Company Z Score Analysis
Lantern Pharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Lantern Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Lantern Pharma is extremely important. It helps to project a fair market value of Lantern Stock properly, considering its historical fundamentals such as Z Score. Since Lantern Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lantern Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lantern Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Lantern Pharma has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Lantern Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lantern Pharma from analyzing Lantern Pharma's financial statements. These drivers represent accounts that assess Lantern Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lantern Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 119.8M | 87.0M | 65.5M | 46.4M | 53.4M | 92.6M | |
| Enterprise Value | 100.6M | 35.7M | 28.4M | 24.7M | 28.4M | 27.0M |
Lantern Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lantern Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lantern Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Lantern Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Lantern Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lantern Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lantern Pharma's value.| Shares | Westside Investment Management, Inc. | 2024-12-31 | 30.6 K | Horizon Asset Management Inc/ny | 2024-12-31 | 28.8 K | Sigma Planning Corp | 2024-12-31 | 28.4 K | Ubs Group Ag | 2024-12-31 | 27.7 K | Bank Of New York Mellon Corp | 2024-12-31 | 26.5 K | Susquehanna International Group, Llp | 2024-12-31 | 26.3 K | Davenport & Company Llc | 2024-12-31 | 25.8 K | State Street Corp | 2024-12-31 | 23.7 K | Two Sigma Investments Llc | 2024-12-31 | 16.5 K | Bios Capital Management, Lp | 2024-12-31 | 1.2 M | Vanguard Group Inc | 2024-12-31 | 363.7 K |
Lantern Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 14.62 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Shares Owned By Insiders | 14.71 % | ||||
| Shares Owned By Institutions | 23.33 % | ||||
| Number Of Shares Shorted | 222.16 K | ||||
| Price To Book | 1.59 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 2.47 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Short Ratio | 3.27 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Target Price | 20.5 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 42.38 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
| Net Asset | 43.65 M |
About Lantern Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lantern Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lantern Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lantern Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock: Check out Lantern Pharma Piotroski F Score and Lantern Pharma Valuation analysis. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.